INTRODUCTION
It has only recently been appreciated that patients with glucagon-producing pancreatic tumors may have a constellation of conditions which include a dermatitis termed necrolytic migratory erythema, weight loss, anemia, stomatitis, impaired glucose tolerance, hypoaminoacidemia, and elevated plasma glucagon levels (1, 2) . Patients with these conditions have been considered as having the glucagonoma syndrome (1) . With the availability of the glucagon radioimmunoassay and a growing awareness of this syndrome, increasing numbers of patients with this disorder are being found. Five patients with glucagon-producing tumors have recently been evaluated by us, providing an opportunity to characterize the different forms of plasma glucagon immunoreactivity and to determine whether neoplastic alpha cells, like insulinomas (3), secrete increased amounts of an immunoreactive moiety, larger than the normal predominant secretory product.
METHODS

Patients
Patient J. D. A 40-yr-old male was admitted to the Massachusetts General Hospital in November 1974, with a 2-yr history of weight loss and a 7-mo history of a skin rash, which was later considered typical of necrolytic migratory erythema. In addition, he had an abnormal glucose tolerance test (fasting plasma glucose, 95 mg/dl; 1 h, 211; and 2 h, 174), stomatitis, anemia, and hepatomegaly. Hypoaminoacidemia was present, and a fasting immunoreactive glucagon level was 2,200 pg/ml. A needle biopsy of the liver showed small, regular tumor cells, and glucagon was demonstrated in these cells using the horseradish peroxidase technique with a rabbit antiglucagon antibody. A selective celiac angiogram revealed a focal area of hypervascularity in the body of the pancreas and multiple discrete hepatic masses. This patient has been described in greater detail as a clinicopathological exercise (4 pneumonia. She initially responded to an infusion of insulin, but then developed focal motor seizures and expired. Necropsy, 6 h after death, revealed cerebral thrombosis, bronchopneumonia, myocardial infarction, and a 0.4-cm nodule protruding from the body of the pancreas. This was a well-differentiated islet cell carcinoma with distinct invasion at the periphery of the lesion. The Grimelius silver strain was positive, the tumor cells showing characteristic alpha cell granules. Electron microscopy likewise showed alpha cell-like granules. Large amounts of glucagon immunoreactivity were found in the tumor by immunofluorescence. Serum withdrawn at necropsy from the subelavian vein had an immunoreactive glucagon value of 1,400 pg/ml. To rule out the possibility that this elevation was a postmortem artifact, serum was obtained from seven postmortem control cases. The necropsy interval varied between 6 and 24 h and glucagon levels ranged between 23 and 191 pg/ml.
Collection of samples 100 g of glucose as Dexicola was given to patients F. L. and H. E., and the samples used for the analysis in Table II were drawn 30 min later. For patient F. L., an intravenous infusion of glucose (100 mg/min) was begun 45 min after the oral glucose and this was continued until 260 min. In addition, 25 g glucose was given intravenously between 55 and 60 min. A sample for fractionation was drawn at 240 min. Arginine was infused intravenously into patients F. L. and M. C. at the rate of 12 mg/kg per min with samples drawn 30 min after the initiation of the infusion. During surgery, a sample was obtained from the splenic vein of patient H. E., and 1 min before this, a peripheral venous specimen was drawn. Similarly, at surgery, a sample was drawn from a vein draining the tumor of patient F. L. and a sample from the splenic artery was obtained as well. The blood samples were collected in tubes containing 500 U Trasylol (Delbay Pharmaceuticals, Bloomfield, N. J.) and either 1 Table I .
Secretion by Glucagonomas 327 Table I .
Before surgical removal, samples were obtained from veins draining the tumors of two patients. When compared with a peripheral venous sample in one patient and an arterial sample in the other, a marked increment of total glucagon immunoreactivity was seen in the venous effluent (Table III) . As with the secretory changes described above, most of the increase was accounted for by peak C material. In addition, however, there was a clear increment in the 9,000-mol wt, peak B, which was particularly obvious in patient H. E. Peak A immunoreactivity also appeared to be increased. Thus, tumor drainage studies indicate that these two glucagonomas secrete primarily 3,500-mol wt glucagon and relatively smaller amounts of the 9,000-mol wt moiety. Further studies were performed to compare the immunoreactive characteristics of peaks B and C with glucagon standard. Plasma from two patients was chromatographed and fractions of peak B and C were separately pooled (patient H. E., 24-31, and 42-46; patient J. D., 23-28, and 41-42). When different volumes from each pool were assayed, parallel displacement curves were found, indicating similar immunologic reactivity of these components with antiserum 30K (Fig. 3) . DISCUSSION In recent years the heterogeneity of glucagon immunoreactivity in human plasma has become increasingly complex, and at least five forms have thus far been described. Total plasma glucagon immunoreactivity in fasting normal man is found to be approximately 100 pg/ml in most laboratories. The majority of this glucagon immunoreactivity, although there is considerable individual variation, is accounted for by a moiety with an estimated mol wt of 160,000 which has been termed the interference factor (5, 9), big plasma glucagon (7), or perhaps more accurately, big plasma glucagon immunoreactivity. This fraction makes up about 55% of the total glucagon immunoreactivity (7) (8) (9) . Most of the remaining glucagon immunoreactivity, approximately 35%, is accounted for by a 3,500-mol wt glucagon (7) (8) (9) ). An additional component, which has a mol wt of 9,000 (7, 8) , may be a precursor form of glucagon and is perhaps identical to material with a similar molecular size called large glucagon immunoreactivity which has been identified in pancreatic tissue extracts (10). This is not usually found in the plasma of normal subjects but is consistently seen in patients with renal failure (8) . A 10,000-20,000-mol wt form has recently been described in a family with increased levels of total glucagon immunoreactivity (11) and Valverde et al. (7) have found a smaller 2,000-mol wt form which is present in very small amounts.
Patients with glucagonomas have an increased level of total glucagon immunoreactivity as would be expected from their large alpha cell mass, and after fractionation much of this material elutes as 3,500 mol wt, "true" glucagon. In addition, the concentration of the 9,000-dalton form is markedly increased, both in terms of absolute amount and also in a relative sense when compared with the quantity of true glucagon. After the administration of various alpha cell effectors, such as glucose given orally or intravenously, or intravenous arginine, there are significant changes in total glucagon immunoreactivity which presumably reflect changes in alpha cell secretion. The increase of glucagon after oral glucose in two of our patients contrasts with the depression found in normal subjects (12) , but has previously been reported (13) . Most of the increase after glucose or arginine administration can be accounted for by the 3,500-mol wt glucagon, but there is also a contribution from the 9,000-mol wt form. Further evidence that this larger form is a secretory product of the neoplastic alpha cells is provided by the finding of increased levels of the 9,000-dalton species in the venous effluent from two tumors. It is not clear whether impaired clearance mechanisms may also have contributed to the increased glucagon levels because specific clearance studies were not performed. However, renal function as assessed by blood urea nitrogen and creatinine was normal in four of the patients.
The size of peak A material, which is greater than 9,000 daltons, has not be.n determined accurately in this study, but it may represent big plasma glucagon immunoreactivity which has previously been found to have an approximate mol wt of 160,000 daltons (7, 8) . The suggestion that this void volume material is secreted (Table III) cursor has not been conclusively proven, there is persuasive evidence that a larger molecule (or molecules) is sequentially cleaved to glucagon (14) . Studies in islet tissue from a number of species including humans (14) (15) (16) (17) indicate that [3H]tryptophane is incorporated into a peptide of about 9,000 daltons. In addition, material of this weight with glucagon immunoreactivity has been found in pancreatic extracts from several species (10). It thus seems likely that one of what might be several glucagon precursor forms has a mol wt of about 9,000. With the present data indicating that the 9,000-dalton species of glucagonoma patients is an alpha cell secretory product, it is reasonable to postulate that this material represents a biosynthetic precursor of glucagon. It may be significant that the immunologic displacement curve of peak B material is parallel to the curves of glucagon standard and peak C. This suggests that the 9,000-mol wt species and true glucagon have common antigenic determinants. Despite this immunologic similarity, the 9,000-dalton material found in pancreatic tissue, which may be identical to the plasma component of the same size, is devoid of glycogenolygic activity (10 
